Comparing the "success" and "failure" groups (Table 4), the area and density of epithelial microcysts were higher in success group but without reaching statistical significance (p > 0.05).
Different hypotheses on epithelial microcysts have been drawn; they are supposed to be hallmarks of transcleral and transconjunctival aqueous percolation or the result of an epithelial disruption, in particular a degeneration at goblet cells level .
Grade 3/4 treatment emergent adverse events (TEAEs) (>1 patient) were keratitis (15%), corneal epithelial microcysts
(8%), hemiparesis (6%), hyperglycemia (6%), muscular weakness (6%), seizure (6%), blurred vision (4%) and ulcerative keratitis (4%).The most common TEAEs (?25% patients) in this study arm were blurred vision (60%), headache (29%), photophobia (29%), dry eye (27%), eye pain (27%), and fatigue (27%).
A history of previous trauma to the eye, recurrent episodes of pain on waking, family history of RCES and epithelial microcysts
make diagnosis straightforward.
with degeneration of basal epithelial cells are associated with the use of cytarabine16.
Ophthalmologic consultation showed bilateral multiple diffuse corneal epithelial microcysts and mild superficial punctate epitheliopathy (Figure 1).
Systemic use at high doses may also produce corneal and conjunctival epithelial toxicity, with conjunctival hyperemia, punctate keratopathy, and corneal epithelial microcysts (4).
Epithelial oedema characterises the third stage and fine epithelial microcysts
are noted with irregular surface texture observed on sclerotic scatter.
In patients with (ABMD) and a history of RCES, the HRT II RCM showed an abnormal epithelial basement membrane protruding forward into the corneal epithelium, the presence of epithelial microcysts and normal superficial epithelial cells and stroma.
In patients with a history of previous trauma to the involved eye, episodes of pain on awakening, and epithelial microcysts, the diagnosis constitutes minimal clinical challenge.